-   Training & Support

[Expand/Collapse all sections]Expand all

This document outlines details of PBS-subsidised trastuzumab and
trastuzumab emtansine for patients with early human epidermal growth
factor receptor 2 (HER2) positive breast cancer (EBC), and lapatinib,
pertuzumab, trastuzumab, trastuzumab deruxtecan and trastuzumab
emtansine, for patients with metastatic (Stage IV) HER2 positive breast
cancer (metBC), often referred to as 'late stage breast cancer'.

Breast cancer and listing dates

Breast cancer is a disease where some breast cells grow out of control
and form a lump or a tumour that can spread to other parts of the body.
It is PBS-listed as early HER2 positive breast cancer and metastatic
(Stage IV) HER2 positive breast cancer.

Listing dates:

Early HER2 positive Breast Cancer (EBC)

-   trastuzumab - 1 October 2006
-   trastuzumab emtansine - 1 April 2020

Metastatic (Stage IV) HER2 positive BC (metBC)

-   lapatinib - 1 May 2008
-   pertuzumab - 1 July 2015
-   trastuzumab - 1 July 2015
-   trastuzumab emtansine - 1 July 2015
-   trastuzumab deruxtecan - 1 November 2023

See Written Authority Required Drugs, for more information.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains links to application forms, contact details,
item and restriction codes, the PBS schedule and the Services Australia
website.

Related links

Efficient Funding of Chemotherapy (EFC) changes in Pharmaceutical
Benefits Scheme (PBS)

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Process telephone Authority approval application

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
